Melange Combination Tablet
NDC Package 62106-1235-2
Package Information
Melange Combination (calcarea sulphurica, calcium phosphoricum, kali muriaticum, kalium phosphoricum, kali sulphuricum, magnesia phosphorica, natrum muriaticum, natrum phosphoricum, natrium sulfuricum, calcarea fluorica, ferrum phosphoricum, silicea) tablets is uses Helps to maintain general mineral metabolism and good health. This formulation utilizes a tablet delivery system. Marketed by Seroyal Usa, this product is identified by NDC 62106-1235.
Identification & Billing
Clinical Specifications
- CALCIUM FLUORIDE 12 [hp_X]/1
- CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS 6 [hp_X]/1
- CALCIUM SULFATE ANHYDROUS 6 [hp_X]/1
- FERROSOFERRIC PHOSPHATE 12 [hp_X]/1
- MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE 6 [hp_X]/1
- POTASSIUM CHLORIDE 6 [hp_X]/1
- POTASSIUM PHOSPHATE, DIBASIC 6 [hp_X]/1
- POTASSIUM SULFATE 6 [hp_X]/1
- SILICON DIOXIDE 12 [hp_X]/1
- SODIUM CHLORIDE 6 [hp_X]/1
- SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE 6 [hp_X]/1
- SODIUM SULFATE 6 [hp_X]/1
- Blood Coagulation Factor - [EPC] (Established Pharmacologic Class)
- Calcium - [CS]
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Cations, Divalent - [CS]
- Increased Coagulation Factor Activity - [PE] (Physiologic Effect)
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Inhibition Small Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Magnesium Ion Exchange Activity - [MoA] (Mechanism of Action)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Potassium Compounds - [CS]
- Potassium Salt - [EPC] (Established Pharmacologic Class)
- Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
Regulatory & Marketing
Hierarchy Structure
- 62106 - Seroyal Usa
- 62106-1235 - Melange Combination
- 62106-1235-2 - 1 BOTTLE, GLASS in 1 BOX / 100 TABLET in 1 BOTTLE, GLASS
- 62106-1235 - Melange Combination
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 62106-1235-2 identifies a specific commercial package of 1 bottle, glass in 1 box / 100 tablet in 1 bottle, glass of Melange Combination, a human over the counter drug labeled by Seroyal Usa. This tablet is formulated for oral use and contains calcium fluoride; calcium phosphate, dibasic, anhydrous; calcium sulfate anhydrous; ferrosoferric phosphate; magnesium phosphate, dibasic trihydrate; potassium chloride; potassium phosphate, dibasic; potassium sulfate; silicon dioxide; sodium chloride; sodium phosphate, dibasic, heptahydrate; sodium sulfate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Seroyal Usa on December 12, 2014. The current certification is valid through December 31, 2026.
How is this Seroyal Usa product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 62106123502. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.